Stock search

Ticker or company name

Compare stocks

Market: US

  • EWEdwards Lifesciences
  • BDXBecton Dickinson
  • BSXBoston Scientific

Add stock

Ticker or company

Summary

EW
Edwards Lifesciences
$107,11Down −0,04%
Year: Up +24%
56/100Ratio would watch
Open stock page
BDX
Becton Dickinson
$216,47Down −0,72%
Year: Up +44%
38/100Ratio would not consider buying
Open stock page
BSX
Boston Scientific
$43,69Down −1,47%
Year: Down −58%
83/100Best scoreRatio would consider buying
Open stock page

Verdict

BSX has the best score (83). EW grows revenue the fastest. BSX is the cheapest by forward P/E. EW has the lowest debt load. BSX has the highest net margin.

Verdict by our methodology based on current metrics. Not an investment recommendation.

Traffic light — 10 checks

CheckEW5 ✓ 0 — 4 ✕BDX2 ✓ 2 — 4 ✕BSX6 ✓ 3 — 0 ✕
P/E vs its history60,351,818,4
P/E vs industry60,351,818,4
Forward P/E35,514,914,0
Revenue growth, YoY+13,4%−2,6%+8,9%
EPS growth, YoY−23,7%−39,4%+26,2%
Net margin15,2%4,5%16,6%
Net debt / EBITDA−2,52,9−0,1
Free cash flow$1,42 bnn/a—$3,33 bn
Share count over a year−1,4%−4,2%−2,9%
Cash runwayn/anot neededn/anot neededn/anot needed

Metrics

Best WorstNo mark — in between

Metric · betterEWTTMBDXTTMBSXTTMIndustry medianTTM
P/E TTM ↓Worst: 60,351,8Best: 18,425,1
Forward P/E ↓Worst: 35,514,9Best: 14,016,2
PEG ↓n/a−27,10,72,2
P/S TTM ↓Worst: 9,2Best: 2,93,12,2
EV/EBITDA ↓Worst: 43,816,4Best: 15,617,3
P/FCF ↓Worst: 42,621,5Best: 19,319,5

Price, %

  • EWn/a
  • BDXn/a
  • BSXn/a

Returns

Best WorstNo mark — in between

PeriodEWBDXBSX
1 yearn/an/an/a
3 yearsn/an/an/a
5 yearsn/an/an/a
All timen/an/an/a

“Per year” is the average annual return: 90% growth over 3 years is 23,9% per year, not 30%. “All time” starts at the IPO, so only “per year” compares fairly. Prices adjusted for splits, dividends reinvested.

Analysts and insiders

Best WorstNo mark — in between

EWBDXBSX
Share of “buy”Best: 82%Worst: 57%65%
Beat the forecastWorst: 3 of 4Best: 4 of 4Best: 4 of 4
Average “surprise”Worst: +0,7%Best: +2,2%+1,5%
Insiders over 12 monthssales $34,0 msales $3,38 msales $6,76 m

Details are on each stock page.